Matches in SemOpenAlex for { <https://semopenalex.org/work/W2033268766> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W2033268766 endingPage "83" @default.
- W2033268766 startingPage "80" @default.
- W2033268766 abstract "There is currently no effective therapy for men with metastatic prostate cancer who relapse after androgen ablation. Prolonged administration of effective concentrations of standard chemotherapeutic agents is usually not possible because of dose-limiting systemic toxicities. A new strategy to target cytotoxic agents specifically to sites of metastatic prostate cancer while avoiding systemic toxicity would be to develop prodrugs that are inactive when given systemically but become activated when processed proteolytically within prostate cancer metastases by prostate-specific antigen (PSA). In this study, the in vivo activity of a prodrug consisting of doxorubicin (Dox) conjugated to a PSA-specific peptide carrier is described.Nude mice bearing PSA-producing human prostate cancer xenografts were treated either intraperitoneally (IP) or by continuous infusion with the Dox prodrug. Toxicity (weight loss, death) and antitumor efficacy (tumor volume changes) were determined.The PSA-peptide Dox prodrug had no discernible systemic toxicity when given at four times the 100% lethal Dox equivalent dose. An IP dose of 60 mg/kg/week x 4 weeks resulted in a 57% decrease in tumor weight vs. control after 40 days. A 25 mg/kg/week dose given by continuous infusion produced a similar decrease in tumor weight vs. control.The PSA-specific peptide/doxorubicin prodrug can be used to deliver higher intratumoral levels of Dox for longer duration while avoiding systemic toxicity. In addition, these results validate the specificity of the PSA-specific peptide as a targetable drug carrier. This PSA-specific peptide could also be used as a carrier to target a wide variety of cytotoxic agents for specific activation within sites of metastatic prostate cancer." @default.
- W2033268766 created "2016-06-24" @default.
- W2033268766 creator A5001771354 @default.
- W2033268766 creator A5047493296 @default.
- W2033268766 date "2000-01-01" @default.
- W2033268766 modified "2023-09-23" @default.
- W2033268766 title "In Vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts" @default.
- W2033268766 cites W1845134010 @default.
- W2033268766 cites W1865508414 @default.
- W2033268766 cites W1964907301 @default.
- W2033268766 cites W1978409389 @default.
- W2033268766 cites W1984749582 @default.
- W2033268766 cites W2019490921 @default.
- W2033268766 cites W2035808001 @default.
- W2033268766 cites W2172433780 @default.
- W2033268766 doi "https://doi.org/10.1002/1097-0045(20000915)45:1<80::aid-pros10>3.0.co;2-q" @default.
- W2033268766 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10960846" @default.
- W2033268766 hasPublicationYear "2000" @default.
- W2033268766 type Work @default.
- W2033268766 sameAs 2033268766 @default.
- W2033268766 citedByCount "58" @default.
- W2033268766 countsByYear W20332687662012 @default.
- W2033268766 countsByYear W20332687662013 @default.
- W2033268766 countsByYear W20332687662014 @default.
- W2033268766 countsByYear W20332687662015 @default.
- W2033268766 countsByYear W20332687662016 @default.
- W2033268766 countsByYear W20332687662017 @default.
- W2033268766 countsByYear W20332687662019 @default.
- W2033268766 countsByYear W20332687662020 @default.
- W2033268766 countsByYear W20332687662021 @default.
- W2033268766 crossrefType "journal-article" @default.
- W2033268766 hasAuthorship W2033268766A5001771354 @default.
- W2033268766 hasAuthorship W2033268766A5047493296 @default.
- W2033268766 hasConcept C108215921 @default.
- W2033268766 hasConcept C121608353 @default.
- W2033268766 hasConcept C126322002 @default.
- W2033268766 hasConcept C150903083 @default.
- W2033268766 hasConcept C207001950 @default.
- W2033268766 hasConcept C2776235491 @default.
- W2033268766 hasConcept C2776694085 @default.
- W2033268766 hasConcept C2780192828 @default.
- W2033268766 hasConcept C2781303535 @default.
- W2033268766 hasConcept C29730261 @default.
- W2033268766 hasConcept C502942594 @default.
- W2033268766 hasConcept C71924100 @default.
- W2033268766 hasConcept C86803240 @default.
- W2033268766 hasConcept C98274493 @default.
- W2033268766 hasConceptScore W2033268766C108215921 @default.
- W2033268766 hasConceptScore W2033268766C121608353 @default.
- W2033268766 hasConceptScore W2033268766C126322002 @default.
- W2033268766 hasConceptScore W2033268766C150903083 @default.
- W2033268766 hasConceptScore W2033268766C207001950 @default.
- W2033268766 hasConceptScore W2033268766C2776235491 @default.
- W2033268766 hasConceptScore W2033268766C2776694085 @default.
- W2033268766 hasConceptScore W2033268766C2780192828 @default.
- W2033268766 hasConceptScore W2033268766C2781303535 @default.
- W2033268766 hasConceptScore W2033268766C29730261 @default.
- W2033268766 hasConceptScore W2033268766C502942594 @default.
- W2033268766 hasConceptScore W2033268766C71924100 @default.
- W2033268766 hasConceptScore W2033268766C86803240 @default.
- W2033268766 hasConceptScore W2033268766C98274493 @default.
- W2033268766 hasIssue "1" @default.
- W2033268766 hasLocation W20332687661 @default.
- W2033268766 hasLocation W20332687662 @default.
- W2033268766 hasOpenAccess W2033268766 @default.
- W2033268766 hasPrimaryLocation W20332687661 @default.
- W2033268766 hasRelatedWork W1979430403 @default.
- W2033268766 hasRelatedWork W1990453785 @default.
- W2033268766 hasRelatedWork W2007724183 @default.
- W2033268766 hasRelatedWork W2035824401 @default.
- W2033268766 hasRelatedWork W2066486774 @default.
- W2033268766 hasRelatedWork W2082005651 @default.
- W2033268766 hasRelatedWork W2102948990 @default.
- W2033268766 hasRelatedWork W2190794004 @default.
- W2033268766 hasRelatedWork W3199803549 @default.
- W2033268766 hasRelatedWork W4206587034 @default.
- W2033268766 hasVolume "45" @default.
- W2033268766 isParatext "false" @default.
- W2033268766 isRetracted "false" @default.
- W2033268766 magId "2033268766" @default.
- W2033268766 workType "article" @default.